Compare ATMU & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATMU | LGND |
|---|---|---|
| Founded | 1958 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | 2023 | N/A |
| Metric | ATMU | LGND |
|---|---|---|
| Price | $55.48 | $209.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $59.75 | ★ $245.00 |
| AVG Volume (30 Days) | ★ 675.9K | 170.9K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | ★ 12.61 | N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $1,764,300,000.00 | N/A |
| Revenue This Year | $15.23 | $0.74 |
| Revenue Next Year | $4.28 | $19.04 |
| P/E Ratio | ★ $22.64 | $76.27 |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $30.94 | $93.58 |
| 52 Week High | $66.50 | $227.92 |
| Indicator | ATMU | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 34.66 | 55.79 |
| Support Level | $51.05 | $179.55 |
| Resistance Level | $58.18 | $227.92 |
| Average True Range (ATR) | 1.89 | 9.82 |
| MACD | -0.75 | 0.20 |
| Stochastic Oscillator | 4.40 | 40.36 |
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. The company designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.